O'DREAMS aims to create a common structure in INSERM U1192 PRISM (Proteomics, Inflammatory Response and Mass Spectrometry) and Oncovet Clinical Research (OCR). The joint O'DREAMS team will conduct research in oncology through both technological and therapeutic developments. Two areas of research will be developed: Axis 1 — Technological developments: creation of real-time non-invasive diagnostic instruments, usable directly at the operating room. Axis 2 — Therapeutic developments: oncoimmunology project by remote reactivation of tumour-associated macrophages and immunomonitoring. All the developments will be carried out on the patients dogs of the company OCR. The creation and structuring of a joint research and development team between the PRISM laboratory and the OCR company has multiple socio-economic implications and implications.